Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2024年5月31日 - 12:20AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
May, 2024
Commission File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer
must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized
(the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes
¨ No x
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED
(Registrant) |
|
|
Date: May 30, 2024 |
By: |
/s/ K Randhir Singh |
|
|
Name: |
K Randhir Singh |
|
|
Title: |
Company Secretary |
Exhibit 99.1
|
Dr.
Reddy’s Laboratories Ltd.
8-2-337,
Road No. 3, Banjara Hills,
Hyderabad
- 500 034, Telangana,
India.
CIN
: L85195TG1984PLC004507
Tel
: +91 40 4900 2900
Fax :
+91 40 4900 2999
Email
: mail@drreddys.com
www.drreddys.com |
May
30, 2024
National
Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE
Limited (Scrip Code: 500124)
New
York Stock Exchange Inc. (Stock Code: RDY)
NSE
IFSC Ltd (Stock Code: DRREDDY)
Dear
Sir/Madam,
Sub: | Disclosure
pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015 |
This
is in furtherance to our intimation dated January 30, 2024 and May 24, 2024, wherein we have informed about the investment by the Company
in equity shares of Aurigene Oncology Limited (“AOL”) (formerly, Aurigene Discovery Technologies Limited), a wholly-owned
subsidiary of the Company, upto an amount of Rs. 6,500 million, and AOL will make similar investment in equity shares of Aurigene Pharmaceutical
Services Limited (“APSL”), a wholly-owned subsidiary of AOL and a step-down wholly-owned subsidiary of the Company.
In
this connection, we further inform that AOL has made an investment of Rs. 649,99,99,520/- in APSL and APSL has allotted 11,60,71,420
equity shares of Rs. 10 each at a premium of Rs. 46/- per share to AOL on May 30, 2024.
The
details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123
dated July 13, 2023, with respect to the above fund infusion is given in Annexure enclosed herewith.
This
is for your information and records.
Thanking
you.
Yours
faithfully,
For
Dr. Reddy’s Laboratories Limited
K
Randhir Singh
Company
Secretary, Compliance Officer and Head-CSR
Encl:
as above
Annexure
Disclosure
under Part A Para A(i) of Schedule III read with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations,
2015
Sl.
No |
Particulars |
Description |
1 |
Name
of the target entity, details in brief such as size, turnover etc.
|
Aurigene
Pharmaceutical Services Limited (“APSL”), a wholly-owned subsidiary of Aurigene Oncology Limited (“AOL”)
(formerly, Aurigene Discovery Technologies Limited), and a step down wholly-owned subsidiary of the Company. The fund infused by
AOL in APSL is to support the capex and working capital requirements of APSL. The turnover of APSL for FY2024 was Rs. 443 Crores.
|
2 |
Whether
the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any
interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms-length” |
The
investment in APSL is a related party transaction, as AOL and APSL are wholly owned subsidiaries and accordingly a related party
to the Company. The investment is done based on valuation report of an Independent Valuer and on arm’s length basis. Except
as stated above, the promoter/ promoter group/ group companies have no interest in AOL and APSL. |
3 |
Industry
to which the entity being acquired belongs |
APSL
is a contract research, development, and manufacturing organization (CRO/CDMO) providing end-to-end solutions in chemistry, and biology
[discovery, development and manufacturing]. |
4 |
Objects
and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business
is outside the main line of business of the listed entity) |
The
fund infused by AOL in APSL is to support the capex and working capital requirements of APSL. |
5 |
Brief
details of any governmental or regulatory approvals required for the acquisition |
Not
applicable. |
6 |
Indicative
time period for completion of the acquisition |
APSL
has allotted 11,60,71,420 Equity shares of Rs.10 each at a premium of Rs. 46/- to AOL on May 30, 2024. |
7 |
Nature
of consideration- whether cash consideration or share swap and details of the same |
Cash
consideration |
8 |
Cost
of acquisition or the price at which the shares are acquired |
Cash
consideration of Rs. 649,99,99,520/- towards subscription of equity shares of 11,60,71,420 equity shares of Rs.10 each at a premium
of Rs. 46/-. |
9 |
Percentage
of shareholding/ control acquired and/ or number of shares acquired |
APSL
is a wholly owned subsidiary of the AOL and step down wholly owned subsidiary of the Company. |
10 |
Brief
background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years
turnover, country in which the acquired entity has presence and any other significant information (in brief) |
APSL
is a contract research, development, and manufacturing organization (CRO/CDMO) providing end-to-end solutions in chemistry, and biology
[discovery, development and manufacturing]. The company was incorporated on 16th of September, 2019. The turnover of the
company for the previous 3 years is shown in below table:
|
|
|
FY2024 |
Rs.
443 Crores |
|
|
|
FY2023 |
Rs.
331 Crores |
|
|
|
FY2022 |
Rs.
361 Crores |
|
Dr Reddys Laboratories (NYSE:RDY)
過去 株価チャート
から 8 2024 まで 9 2024
Dr Reddys Laboratories (NYSE:RDY)
過去 株価チャート
から 9 2023 まで 9 2024